Akèy › Leksemi mieloïd egi › Minnesota › Rochester
Etid klinik pou Leksemi mieloïd egi nan Rochester, MN
12 etid pou Leksemi mieloïd egi ap chèche patisipan nan sit nan ak bò kote Rochester (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Ap rekriteFaz 2
- Mayo Clinic in Rochester, Rochester
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- Mayo Clinic in Rochester, Rochester
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Ap rekriteFaz 3
- Mayo Clinic in Rochester, Rochester
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Ap rekriteFaz 1/2
- Mayo Clinic, Rochester
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Ap rekriteFaz 3
- US-Rochester MN-MAYOMN, Rochester
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Ap rekriteFaz 1/2
- Mayo Clinic in Rochester, Rochester
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Ap rekriteFaz 1
- Mayo Clinic in Rochester, Rochester
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Ap rekriteFaz 1/2
- Mayo Clinic Comprehensive Cancer Center, Rochester
Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy
Ap rekriteEtid obsèvasyon
- Mayo Clinic in Rochester, Rochester
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Ap rekriteFaz 1
- Mayo Clinic - Rochester, Rochester
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
Ap rekriteFaz 1
- Mayo Clinic, Rochester
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
Ap rekriteVolontè an sante akeyi
- Mayo Clinic, Rochester
Etid Leksemi mieloïd egi nan lòt vil
- Houston, TX85 etid
- New York City, NY51 etid
- Boston, MA44 etid
- Baldwin Park, CA40 etid
- Seattle, WA40 etid
- Columbus, OH35 etid
- Philadelphia, PA34 etid
- Durham, NC33 etid
- Atlanta, GA30 etid
- Tampa, FL29 etid
- Chicago, IL26 etid
- Portland, OR25 etid
Lòt etid nan Rochester
- Kansè nan tete42 etid
- Kansè Poumon ki pa ti selil37 etid
- Kansè Metastatik31 etid
- Kansè (tout kalite)30 etid
- Kansè kolorektal29 etid
- Kansè ovè29 etid
- Myelom Miltip24 etid
- Kansè pwostat22 etid
- Ensifizyans kadyak22 etid
- Kansè pankreyas22 etid
- Kansè poumon20 etid
- Kansè Endomèt20 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.